Sign up
Pharma Capital
Market: AIM
52-week High/Low: 4,200.00p / 18.78p
Sector: Pharma & Biotech
Market Cap: 12.86M

IXICO is dedicated to delivering insights in neuroscience. The company's mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health technologies, bringing safe and effective treatment to patients sooner. 

IXICO’s digital platform and Artificial Intelligence (AI) software are used by...


Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in IXICO PLC

IXICO PLC Snapshot

As a trusted partner to the global biopharma industry, our technology enabled specialty services are used to, select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.

Our strong scientific heritage and deep understanding of neurological diseases enable us to collaborate with clinical, academic and pharmaceutical partners to develop and deploy new digital technologies targeted at improving the assessment of patient outcomes.




Our Values

We are neuroscience experts in image data management and analysis.

Our greatest assets are our talented people developing and deploying innovative digital technologies.

Quality drives our operational excellence. We support our people to be the best they can be through continuous learning and development.

We conduct our business to the highest ethical standards and strive to be a trusted partner of choice.


Neuroscience Expertise

Since 2004 our technology, scientific expertise and clinical data management and analysis capabilities have been selected to support clinical trials for the majority of the top pharmaceutical and speciality biotechnology companies.

For  further infromation please click here 


Neurological disease focus


Alzheimer’s Disease (AD)
AD is a chronic neurodegenerative disease and is represented in 60-70% of cases of dementia. In 2015, there were approximately 29.8 million people worldwide living with AD. It affects around 6% of people aged 65+ years. There are currently no treatments to halt or reverse its progression. There is significant ongoing research to better understand and treat AD. We have supported important AD research since 2007 and continue to assist many pharmaceutical companies in their search for novel therapies.




Parkinson’s Disease (PD)
PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD. The combined direct and indirect cost of PD, including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone. There has been significant research over the past 50 years, resulting in important discoveries and treatments which provide relief. We first supported a clinical study for PD in 2016.

Huntington’s Disease (HD)
HD is a rare genetic neurodegenerative disorder that affects the patient’s normal movement, cognition and behaviour. HD is more common in people of Western European descent than in those of Asian or African ancestry, affecting approximately 5-7 people per 100,000 in Western countries. There are currently no effective marketed treatments for HD. Interest in developing therapeutics to treat the disease within the pharmaceutical industry is significant with a large number of pharmaceutical and biotechnology companies working in this indication. We have supported important research in HD since 2007.

Progressive Supranuclear Palsy (PSP)
PSP is a Parkinson’s-like neurological condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. Research suggests around 20,000 people suffer with PSP in the United States alone. There are currently no effective marketed treatments for PSP. There is growing momentum in PSP research and we have supported clinical trials in this area since 2015.

Cerebrovascular Disease
Cerebrovascular diseases are conditions caused by problems that affect the blood supply to the brain and can result in vascular dementia. Cerebrovascular disease primarily occurs with advanced age and the risk increasing after 65 years of age. We have supported cerebrovascular disease research since 2012.

Multiple Sclerosis (MS)
MS is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder affecting the central nervous system, affecting around 2.3 million people globally as of 2015. Ongoing research is focused on developing more effective disease-modifying and symptomatic treatments as well as the creation of therapies for the progressive types of MS. We have been involved in MS since 2015 through our AssessaPML collaboration with Biogen.

Technology Services 



Technology Services


Unique imaging and data management with science – at scale

We have the capability, scale and experience to provide clinical trial services across all trial phases.

Our platform has been developed by our experts as a scalable and secure infrastructure for the standardisation, capture, analysis and reporting of regulatory compliant clinical data. This enables you to make rapid, better informed, clinically meaningful decisions.

For more information please click here 

How we work 

Global, multi-site standardisation

Working with our network of qualified clinical sites worldwide, we deliver innovative, regulatory compliant technology solutions. By providing compliant data standardisation, collection and analysis we support our biopharma clients’ regulatory submission, establishing IXICO as a trusted partner.

Our deep understanding of neuroimaging underpins everything we do. Our multi-disciplinary team support you from project design through to close with our unique end-to-end data management and image analysis platform.



For more information please click here 



Our Board


Charles Spicer

Charles Spicer


Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.


Susan LowtherSusan Lowther


Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc and Finance Director of RiboTargets Limited until its acquisition by Vernalis plc.


Mark WarneMark Warne


Mark joined the Board of IXICO in 2016. He is Head of IP Group’s Healthcare division and has extensive experience in building world-changing healthcare businesses, including portfolio company IPOs, financings and M&A. Mark is a Non-Executive Director of hVIVO plc, Genomics plc, Cronin Group plc and Crysalin Limited.


Giulio CerroniGiulio Cerroni


Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC group, where he transformed the scale of LG’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC group to global investment firm, KKR.


Tim SharpingtonTim Sharpington


Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Previous positions include Chief Executive Officer at Phytopharm PLC and Serentis Limited and Executive Vice President at Vectura PLC. Tim joined the Board of IXICO in 2013 and chairs the Remuneration Committee.


John BradshawJohn Bradshaw


John is a chartered accountant with more than 20 years’ experience as a Chief Financial Officer with venture capital backed and listed companies. He is the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited a FTES250 listed life sciences investment company. He is a non-executive director and Audit Committee Chair of AIM listed companies IXICO PLC and Creo Medical Group PLC. He was previously Chief Financial Officer of Gyrus Group PLC following 11 years at Arthur Andersen in Cambridge and Turin.


Please click here for major shareholders 


4th Floor
Griffin Court
15 Long Lane



IXICO Technologies Inc.
225 Cedar Hill Street
Suite 200
Marlborough, MA 01752


Company Information
IXICO plc is incorporated and registered in England and Wales with registered number 03131723. The Group operates from its headquarters in London, UK.

Registered Office
4th Floor, Griffin Court, 15 Long Lane, London EC1A 9PN

Nominated Advisor and Broker
Shore Capital and Corporate Limited
Bond Street House, 14 Clifford Street, London, W1S 4JU

Shore Capital Stockbrokers Limited
Bond Street House, 14 Clifford Street, London W1S 4JU
T +44 (0)20 7408 4080

Equiniti Registrars Limited
Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA
T +44 (0)871 384 2030

Chartered accountants and statutory auditors
Grant Thornton UK LLP
101 Cambridge Science Park, Milton Road, Cambridge CB4 0FY
T +44 (0)1223 225600

Legal Advisors
Bristows LLP
100 Victoria Embankment, London, EC4Y 0PH
T +44 (0)20 7400 8000

Financial public relations
FTI Consulting LLP
200 Aldersgate, Aldersgate Street, London, EC1A 4HD
T +44 (0)20 3727 1000

View full IXI profile View Profile
View All

Market Reports Including IXI


Executive video interviews


© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.